Mexico / Prospects for Healthcare Ahead of 2024 Election
Mexican voters will be heading to the polls next June for what will be the largest election process in the country’s history with concurrent state and federal elections. The election will…
Regenerative medicine aims to replace or regenerate damaged cells, tissues, or organs, both structurally and functionally, which have lost their optimal biological regulatory condition. Regeneration in nature can occur at the cellular, tissue, organ, structural, and even whole body levels, but in humans is naturally significantly limited with aging.
To achieve a transformational level of technological advancement in this area for humans, RegenerAge is utilizing novel combination applications of biological interventions, including stem cells, soluble regenerative biologics, proprietary nutritional bio-products, functional and regenerative based diets, bioidentical hormone replacement, and skin / aesthetic rejuvenation tools, yielding an unprecedented, integrated option for activating the natural healing processes of the body and maintaining health and wellness.
Regenerative medicine incorporates various fields of science, including genetics, biomedical engineering, tissue engineering, advanced cell technology, and evolutionary dynamics, with the goal of allowing human bodies to recover cellular function, vitality and optimizing its integrated operation.
Smart prevention is the best initial approach for any disease, but once an illness manifests as part of a person’s life, regeneration and repair are invaluable options to restore health and restructure damaged tissues and cells within the human body. Recent biotechnology related advances present wonderful opportunities for RegenerAge to improve outcomes when patients need more than traditional treatments, as well as to increase lifespan and wellness for those conscious about their health and longevity.
RegenerAge is open to working with all types of patients according to their medical status. Our treatments may help patients who suffer from a variety of chronic degenerative diseases including, but not limited to: cardiovascular conditions, diabetes, kidney damage, different types of cancer, auto-immune diseases, CNS degeneration, and hematological disorders.
Contact
Address: BNY Mellon Center 1735 Market Street, Suite 3750 Philadelphia PA 19103 USA
Tel. +52 55 3028 4783
Website: https://regenerage.clinic/es/
Mexican voters will be heading to the polls next June for what will be the largest election process in the country’s history with concurrent state and federal elections. The election will…
The latest from Mexican pharma, including the distribution agreement between Dow and Azelis, Neuraxpharm’s new LatAm subsidiaries in Mexico and Brazil; Landsteiner Scientific’s restructure, and Merck’s plant expansion in Naucalpan.…
Latin America’s patient organisations are today playing a more important role than ever before in developing solutions to the continent’s most pressing healthcare challenges. Given the healthcare gaps that persist,…
Back in Latin America after several years in the US and Europe, Teva LatAm Head and Mexico GM Rodrigo Fernandez explains how the affiliate has adapted its strategy across the…
Mexico, with the second largest pharmaceutical market in Latin America, has a number of strong local pharma industry players. These companies, no longer focused solely on the domestic market, are…
María del Socorro España Lomelí, the executive director of Mexico’s National Association of Manufacturers of Medicines (ANAFAM), speaks to PharmaBoardroom about ANAFAM’s evolving relationship with the Mexican government and the…
Dagoberto Cortés Cervantes, president of Mexico’s National Association of Medicines Manufacturers (ANAFAM) and director of Grupo Sanfer/Hormona Mexico, outlines the expansion strategy that has led the manufacturing group to extend…
The Mexican Association of Pharmaceutical Research Industries (AMIIF) represents the innovative pharmaceutical industry in Mexico, advocating for innovation and promoting dialogue with local authorities. AMIIF’s Executive Director, Cristobal Thompson, discusses…
Latin America (LatAm) Area Lead for Astellas Sandra Ramirez outlines the Japanese company’s presence in the region, its efforts to partner with local stakeholders to improve patient access, and the…
Mexico’s pharma market, the second largest in Latin America and among the top 15 globally, is set to top USD 13 billion in sales by 2028. Despite the encouraging numbers,…
The director of Mexican pharmaceutical industry association CANIFARMA, Rafael Gual Cosío, speaks out about the current contradictions plaguing Mexico’s pharma sector. Gual Cosío highlights the fact that market growth and…
The latest from Latin American pharma, including Moderna’s push to build a regional presence and partnership network; Pfizer’s health equity challenges in the region; and Brazil’s local manufacturing of AstraZeneca’s…
See our Cookie Privacy Policy Here
